Topics

Articles

Latest Q4 2022 results show some progress, but 100% readiness by November looks doubtful.

 DSCSA Compliance Readiness Inches Along, Says HDA Survey 

New federal law introduces significant changes in the design of pharmacy benefit plans with aims to level the playing field between PBMs and their employee healthcare benefit plan clients.

The Consolidated Appropriations Act and PBM Transparency

“Deep learning” IT tools were used to calculate sales volumes and drug class.

IQVIA Study: Illegal Online Pharmacies Cost Pharma $34B in Diverted 2022 US Sales

Innovation and investment in advancing lifesaving therapies for pediatric patients to the commercial stage remains a daunting task, but rapid advances today in modeling and simulation are reducing the hurdles for drugmakers.

Pediatric Medicine: Challenges Abound

As a November deadline looms for industry compliance with an interoperable system for product tracing, there is more urgency in the US pharma supply chain.

Ramping Up DSCSA Readiness Efforts

Senate committee report highlights a lack of visibility in API suppliers.

Rising Drug Shortages Are Garnering Increased Federal Attention

Industry is still scrambling to handle clerical errors of DSCSA transactions.

FDA Finalizes the Definitions of 'Suspect and Illegitimate' Pharma Products 

Event—taking place in Indianapolis—places supply chain education at the forefront. 

HDA’s 2023 Distribution Management Conference Dives into DSCSA Specifics and More

The Pulse online service will provide free resources to enable pharmacy to meet drug traceability rules.

NABP Hopes to Fill a Key Gap in DSCSA Compliance: Local Pharmacies

Initiative intends to facilitate regulatory compliance within the pharma distribution space. 




Legal and Regulatory